Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock
RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.02 (-4.36%)
Close on Oct 19, 2026Market cap $5.94MP/E –Yield –
Reviva Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Reviva Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$11.88M. For fiscal 2025 it was -$20.20M. The highest annual figure on record is -$376.86K in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.20M | – |
| FY2024 | Dec 31, 2024 | -$30.80M | – |
| FY2023 | Dec 31, 2023 | -$39.50M | – |
| FY2022 | Dec 31, 2022 | -$28.23M | – |
| FY2021 | Dec 31, 2021 | -$10.10M | – |
| FY2020 | Dec 31, 2020 | -$2.43M | – |
| FY2019 | Dec 31, 2019 | -$376.86K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.43M | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.98M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.52M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.48M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.87M | – |
| Q3 FY2020 | Nov 30, 2020 | -$352.01K | – |
| Q2 FY2020 | Aug 31, 2020 | -$525.92K | – |
| Q3 FY2019 | Nov 30, 2019 | -$166.02K | – |
| Q2 FY2019 | Aug 31, 2019 | -$94.11K | – |
| Q3 FY2018 | Nov 30, 2018 | -$79.15K | – |
| Q2 FY2018 | Aug 31, 2018 | -$15.67K | – |
See a number that looks wrong?